Tipifarnib

Drug Profile

Tipifarnib

Alternative Names: NSC-702818; R-115777; Zarnestra

Latest Information Update: 12 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Janssen L.P.; Janssen-Cilag; Johnson & Johnson
  • Developer Emory University; H. Lee Moffitt Cancer Center and Research Institute; Janssen-Cilag; Johnson & Johnson; Kura Oncology; National Cancer Institute (USA); Samsung Medical Center; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Quinolones; Small molecules
  • Mechanism of Action Apoptosis stimulants; Farnesyltranstransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Acute myeloid leukaemia
  • Phase II Chronic myelomonocytic leukaemia; Head and neck cancer; Myelodysplastic syndromes; Peripheral T-cell lymphoma; Thyroid cancer; Urogenital cancer
  • Phase I/II Multiple myeloma
  • Discontinued Breast cancer; Glioblastoma; Pancreatic cancer

Most Recent Events

  • 07 Sep 2017 The primary endpoint was met in the topline efficacy data from a phase II trial in Head and Neck cancer released by Kura Oncology
  • 18 Jul 2017 Kura Oncology has patent protection for tipifarnib for Head and neck cancer in USA
  • 13 Jul 2017 Kura Oncology and Foundation Medicine entered a collaboration agreement for patient enrolment in phase II study of tipifarnib in head and neck cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top